CNTXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Stats
本日の出来高	19 946.00
平均出来高	55 784.00
時価総額	22.51M
EPS	$0 ( 2024-03-27 )
次の収益日	( $-0.390 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.940
ATR14	$0.0230 (1.63%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-21	Minai-azary Jennifer Lynn	Buy	160 115	Stock Option (right to buy)
2024-03-21	Levit Alex C.	Buy	153 515	Stock Option (right to buy)
2024-03-21	Lehr Martin A.	Buy	291 402	Stock Option (right to buy)
2023-05-31	Kantoff Philip W.	Buy	25 000	Stock Option (right to buy)
2023-05-31	West Linda	Buy	25 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 72 transactions
Buy: 4 162 098 \| Sell: 2 098 089

Context Therapeutics Inc. 相関

10 最も正の相関
SGH	0.957
KOPN	0.957
PLAB	0.949
ALR	0.941
STER	0.939
ELTK	0.938
MRVL	0.935
XBIT	0.931
EVLO	0.927
CALA	0.927

10 最も負の相関
OPTN	-0.919
SBNYP	-0.909
ASO	-0.901
FANH	-0.899
ATHN	-0.896
PHCF	-0.895
CDAK	-0.885
PAYS	-0.885
MTSI	-0.877
AGFS	-0.876

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Context Therapeutics Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-12 044.00 (0.00 %)
EPS:	$-1.500

FY	2023
収益:	$0
総利益:	$-12 044.00 (0.00 %)
EPS:	$-1.500

FY	2022
収益:	$0
総利益:	$-9 268.00 (0.00 %)
EPS:	$-0.900

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.024

Financial Reports:

No articles found.

Context Therapeutics Inc.

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.